ArticleJournal of experimental & clinical cancer research : CR2023

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

Christopher B Cole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.